Human HIV Vaccine Trial Begins With BRILLIANT 011
South Africa launches the HIV vaccine trial, BRILLIANT 01, testing a new vaccine cocktail designed to prime broadly neutralising antibodies.
HIV Prevention in SA Needs Local Lenacapavir Manufacturing
HIV prevention in South Africa hinges on local drug manufacturing to ensure access, reduce delays, and enable regional health security.
Long-acting Injectable PrEP: Transforming HIV Strategies
Learn how long-acting injectable PrEP can transform HIV responses in South Africa while bridging treatment access gaps.
Lenacapavir Approved for HIV Prevention in South Africa
Lenacapavir has been registered by SAHPRA as an innovative HIV prevention injection. Find out more about its rollout in South Africa.
Lenacapavir Access Under Scrutiny by Health Advocates
Explore the urgent call for lenacapavir access, as advocates seek equitable HIV prevention for all communities worldwide.
Generic HIV Prevention Drug to Cost Just $40 Annually from 2027
Explore the benefits of the generic HIV prevention drug lenacapavir, set to change the landscape of global health by 2027.
Gilead’s Lenacapavir to Reach High-Burden Nations ‘At Cost’
Gilead’s Lenacapavir is set to revolutionise HIV prevention efforts, aiming to protect two million people across affected nations.
HIV Prevention Injection Changes the Game in Treatment
Discover the new HIV prevention injection coming to South Africa. Learn how lenacapavir offers a game-changing alternative to daily pills.
HIV Prevention Injection Changes the Game in Treatment
Discover the new HIV prevention injection coming to South Africa. Learn how lenacapavir offers a game-changing alternative to daily pills.
Sakeliga’s NHI Legal Battle for Constiutional Justice
Learn about Sakeliga's NHI legal battle as they challenge the constitutionality of South Africa's National Health Insurance plan.